A newly designed therapeutic vaccine called TherVacB is being developed as an immunotherapy to cure Hepatitis B Virus (HBV).
TherVacB: A Promising New Approach
TherVacB is an immunotherapy designed to functionally cure chronic Hepatitis B. This innovative approach is different from existing treatments that primarily suppress the virus. The goal is to achieve complete viral control without the need for long-term medication.
Clinical Trial Details
- Timeline: Clinical trials are scheduled to begin in 2024.
- Location: The trials will be conducted in Europe and Africa.
- Purpose: The clinical trials will evaluate the safety and efficacy of TherVacB in patients with chronic HBV infection.
Key Players
A consortium of leading virologists, immunologists, and physicians specialized in treating viral hepatitis is involved in developing and evaluating TherVacB.
Why This is Important
Current treatments for chronic Hepatitis B often require lifelong medication and do not always lead to a complete cure. TherVacB offers the potential for a functional cure, improving the long-term health and quality of life for individuals with HBV.
